Last updated on December 2018

A Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Brief description of study

The Primary Objectives of FX2016-11 and FX2016-12 are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.

Detailed Study Description

This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate the safety and efficacy of FMX103 topical foam containing 1.5% minocycline compared to vehicle, in the treatment of subjects with moderate-to-severe facial papulopustular rosacea. Qualified subjects will be randomized to receive 1 of the following 2 treatments:

  • FMX103 minocycline foam 1.5%
  • Vehicle foam

Clinical Study Identifier: NCT03142451

Contact Investigators or Research Sites near you

Start Over

Premier Research

Foamix Investigational Site # 140
Warren, MI United States

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.